ReviewWorld journal of hepatology2015
Hepatitis C infection in hemodialysis patients: A review.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis.Journal of nephrology · 2022Pooled it
- Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units.The Cochrane database of systematic reviews · 2016Pooled it
- Hepatitis C Virus Infection at the Start of Hemodialysis and During Early Follow-up: Evidence from Two Dialysis Centers.Journal of epidemiology and global health · 2026Observational
- Health seeking behaviour and self-care among hypertensive and diabetics at risk of CKD in Buea, Cameroon.Journal of public health in Africa · 2025Article
- Occult hepatitis C virus infection in hemodialysis patients who achieved a sustained virological response to directly acting antiviral drugs: is it a concern?International urology and nephrology · 2024Article
- Article
- Prevalence of occult hepatitis C virus infection in hemodialysis patients.Caspian journal of internal medicine · 2021Article
- Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.Canadian journal of gastroenterology & hepatology · 2020Article
- Common viral infections in kidney transplant recipients.Kidney research and clinical practice · 2018Review
- Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation.Current infectious disease reports · 2018Review
- Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus.Infection and drug resistance · 2018Article
- Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation.Molecular and clinical oncology · 2017Article
- Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients.Disease markers · 2017Article
- The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation.Clinical and experimental hepatology · 2016Article
- Treatment of chronic hepatitis C virus infection in patients with end-stage renal disease on hemodialysis.Clinical liver disease · 2016Review
- Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?World journal of hepatology · 2016Article
- Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon.World journal of gastroenterology · 2016Review
- Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients.In vivo (Athens, Greece)Observational
- Association between interleukin-6 gene polymorphism and iron regulation in hemodialysis patients infected with HCV.Jornal brasileiro de nefrologiaArticle
- Comparison of diagnostic performance of transcription-mediated amplification with chemiluminescent microparticle immunoassay in the detection of hepatitis C virus in dialysis patient group.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV)-related liver disease is a significant cause of morbidity and mortality in patients with end-stage renal disease (ESRD) who is treated with dialysis or kidney transplantation (KT). The survival rate for HCV-infected renal transplant recipients is better than that for HCV-infected hemodialysis patients on transplant waiting lists. Early diagnosis and treatment HCV infection prior to KT prevents complications post-transplantation and reduces mortality. In addition to screening for anti-HCV antibodies and detecting HCV RNA, percutaneous liver biopsy is particularly valuable for assessing the stage of liver damage in HCV-infected patients, because the stage of fibrosis is important determining optimal treatment for HCV. Studies have been demonstrated that with conventional interferon (IFN) monotherapy or pegylated IFN monotherapy are similar efficacy and safety in HCV-infected hemodialysis patients. Sustained viral responses (SVRs) with these monotherapies have ranged approximately 30% to 40%. Limited reports support the use of IFN and ribavirin combination therapy as antiviral treatment for ESRD patients or patients on hemodialysis. Ribavirin can be started at low dose and careful monitoring for side effects. Patients that show SVR after treatment are strong candidates for KT. It is also generally accepted that ESRD patients with decompensated cirrhosis and portal hypertension should be referred to the liver transplant team for consideration of combined liver-KT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.